PMID- 25676400
OWN - NLM
STAT- MEDLINE
DCOM- 20151105
LR  - 20181202
IS  - 1999-6187 (Electronic)
IS  - 1009-3419 (Print)
IS  - 1009-3419 (Linking)
VI  - 18
IP  - 2
DP  - 2015 Feb
TI  - [Analysis of EML4-ALK gene fusion mutation in patients 
with non-small cell lung 
      cancer].
PG  - 80-4
LID - 10.3779/j.issn.1009-3419.2015.02.05 [doi]
AB  - BACKGROUND: Non-small cell lung cancer (NSCLC) is the main type of lung cancer, 
      and the related locus mutation detection research has become a hot direction of 
      molecular targeted therapy, studying on gene mutation status of echinodem 
      microtubule associated protein like 4-Anaplastic lymphoma kinase (EML4-ALK) and 
      epidermal growth factor receptor (EGFR), detecting the sensitivity of EML4-ALK 
      gene fusion and gene mutation of EGFR. METHODS: EML4-ALK gene fusion in 85 cases 
      of paraffin embedded tumor tissue and adjacent lung tissue was detected with the 
      application of immunohistochemistry (IHC), Scorpions amplification refractory 
      mutation system (Scorpions ARMS) fluorescence quantitative PCR and fluorescence 
      in situ hybridization (FISH) technology, and EGFR gene in 18, 19, 20 and 21 exon 
      mutation status was detected with the application of ARMS method. RESULTS: In 115 
      cases of NSCLC, IHC showed 32 cases with ALK (D5F3) expression, the expression 
      rate was 27.8%; ARMS showed 27 cases with EML4-ALK fusion gene mutation, the 
      mutation detection rate was 23.5%; 53 cases were detected with EGFR mutation, the 
      mutation rate was 46%. While FISH showed 23 cases with EML4-ALK fusion gene 
      mutation, the detection rate was 20%, slightly lower than the ARMS detection 
      results, suggesting that ARMS more sensitive. CONCLUSIONS: The application of 
      IHC, ARMS fluorescence quantitative PCR and FISH technology can make a rapid and 
      accurate evaluation of EML4-ALK gene fusion.
FAU - Wang, Xuzhou
AU  - Wang X
AD  - Department of Pathology, Fuzhou General Hospital of NanJing Military Rejion, 
      Fuzhou 350025, China.
FAU - Chen, Weisheng
AU  - Chen W
AD  - Department of Cardiothoracic Surgery, Fuzhou General Hospital of NanJing Military 
      Rejion, Fuzhou 350025, China.
FAU - Yu, Yinghao
AU  - Yu Y
AD  - Department of Pathology, Fuzhou General Hospital of NanJing Military Rejion, 
      Fuzhou 350025, China.
LA  - chi
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhongguo Fei Ai Za Zhi
JT  - Zhongguo fei ai za zhi = Chinese journal of lung cancer
JID - 101126433
RN  - 0 (EML4-ALK fusion protein, human)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Carcinoma, Non-Small-Cell Lung/enzymology/*genetics
MH  - ErbB Receptors/genetics
MH  - Female
MH  - Gene Fusion
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Lung Neoplasms/*genetics
MH  - Male
MH  - Middle Aged
MH  - *Mutation
MH  - Mutation Rate
MH  - Oncogene Proteins, Fusion/*genetics
PMC - PMC5999844
EDAT- 2015/02/14 06:00
MHDA- 2015/11/06 06:00
PMCR- 2015/02/20
CRDT- 2015/02/14 06:00
PHST- 2015/02/14 06:00 [entrez]
PHST- 2015/02/14 06:00 [pubmed]
PHST- 2015/11/06 06:00 [medline]
PHST- 2015/02/20 00:00 [pmc-release]
AID - zgfazz-18-2-80 [pii]
AID - 10.3779/j.issn.1009-3419.2015.02.05 [doi]
PST - ppublish
SO  - Zhongguo Fei Ai Za Zhi. 2015 Feb;18(2):80-4. doi: 
      10.3779/j.issn.1009-3419.2015.02.05.